Human biomarkers: Can they help us to develop a new tuberculosis vaccine?

7Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The most effective intervention for the control of infectious disease is vaccination. The BCG vaccine, the only licensed vaccine for the prevention of tuberculosis (TB) disease, is only partially effective and a new vaccine is urgently needed. Biomarkers can aid the development of new TB vaccines through discovery of immune mechanisms, early assessment of vaccine immunogenicity or vaccine take and identification of those at greatest risk of disease progression for recruitment into smaller, targeted efficacy trials. The ultimate goal, however, remains a biomarker of TB vaccine efficacy that can be used as a surrogate for a TB disease end point and there remains an urgent need for further research in this area.

Cite

CITATION STYLE

APA

Fletcher, H. A., & Dockrell, H. M. (2016, June 1). Human biomarkers: Can they help us to develop a new tuberculosis vaccine? Future Microbiology. Future Medicine Ltd. https://doi.org/10.2217/fmb.16.15

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free